# US 2011/0086056 A1 · Methods for the early diagnosis of ovarian cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0086056 A1
- Document ID: US20110086056A1
- Status: Published application
- Kind: A1
- Application number: 12/807,390
- Filed: 2010-09-03
- Published: 2011-04-14
- Earliest claimed: 2000-02-22
- Inventors: Timothy J. O'Brien; Martin J. Cannon; Alessandro Santin; John Beard; Kazushi Shigemasa
- Web page: https://patentgrep.com/patent/US20110086056A1

## CPC

- C07K 14/435: from animals; from humans
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C12N 9/6424: {Serine endopeptidases (3.4.21)}
- C12Q 1/37: involving peptidase or proteinase
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/57545: of the ovaries
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- G01N 2333/96433: Serine endopeptidases (3.4.21)
- G01N 2500/20: cell-free systems
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention discloses the protease hepsin is specifically over-expressed in ovarian and other malignancies. A number of hepsin peptides can induce immune responses to hepsin, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies. There is also provided a hepsin protein variant that is useful as a marker for ovarian cancer cells, prostate cancer cells or kidney cancer cells.

## Claims

### Claim 1

An isolated DNA encoding a hepsin protein variant, said variant protein comprising an amino acid sequence shown in SEQ ID NO. 195 or a peptide variant thereof.

### Claim 2 (depends on 1)

The isolated DNA of claim 1, wherein the peptide variant amino acid sequence is shown in SEQ ID NO: 196.

### Claim 3

An isolated and purified hepsin protein variant with an amino acid sequence shown in SEQ ID NO. 195 or a hepsin protein variant peptide thereof with an amino acid sequence shown in SEQ ID NO: 196.

### Claim 4 (depends on 3)

An immunogenic composition, comprising the hepsin protein variant or peptide thereof of claim 3 and an appropriate adjuvant.

### Claim 5 (depends on 3)

A method of vaccinating an individual against hepsin protein variant, comprising:
inoculating an individual with the hepsin protein variant or peptide thereof of claim 3, wherein said hepsin protein variant or peptide elicits an immune response in the individual, thereby vaccinating the individual against hepsin protein variant.

### Claim 6 (depends on 5)

The method of claim 5, wherein said hepsin protein variant or peptide thereof comprises a dendritic cell or is expressed from an expression vector.

### Claim 7 (depends on 5)

The method of claim 5, wherein the individual has or is at risk of getting ovarian cancer, lung cancer, prostate cancer, or colon cancer.

### Claim 8 (depends on 3)

A method of immunotherapy targeted toward hepsin protein variant in an individual, comprising:
a) isolating dendritic cells from the individual;
b) expressing a hepsin protein variant or peptide variant thereof of claim 3 in the dendritic cells;
c) exposing immune cells comprising T cells isolated from the individual to the dendritic cells, wherein said dendritic cells would generate hepsin variant-specific T cells from the immune cells; and
d) transferring the immune cells back to the individual, wherein said immune cells would activate hepsin variant-specific immune responses in the individual, thereby generating immunotherapy targeted toward hepsin protein variant.

### Claim 9 (depends on 8)

The method of claim 8, wherein the individual has, is suspected of having or is at risk of getting ovarian cancer or prostate cancer.

### Claim 10 (depends on 8)

The method of claim 8, wherein expression of hepsin protein variant in the dendritic cells is obtained by transfection, transduction and loading the dendritic cells with a hepsin protein variant or fragment thereof.

### Claim 11 (depends on 3)

A method of monitoring the efficacy of vaccinating an individual with hepsin protein variant or fragment thereof, comprising:
vaccinating the individual with the hepsin protein variant or peptide variant thereof of claim 3;
isolating T cells from the individual; and
measuring immune responses induced by the hepsin variant or fragment thereof, wherein an increased level of immune responses compared to those exhibited by cells from normal individual indicates that the individual has been vaccinated by said hepsin protein variant or fragment thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the immune response is T cell proliferation induced by the hepsin protein variant or peptide variant thereof, frequency of cytokine-secreting T cells specific to the hepsin protein variant or peptide variant thereof and frequency of T cells expressing T cell receptor specific to the hepsin protein variant or peptide variant thereof.

### Claim 13 (depends on 3)

A method of inhibiting hepsin protein variant in a cell, comprising
introducing into the cell an antibody specific for a hepsin protein variant of claim 3, wherein binding of the antibody to the hepsin protein variant or peptide variant thereof inhibits hepsin protein variant in the cell.

### Claim 14

The method of claim, further comprising a therapeutic moiety.

### Claim 15 (depends on 13)

The method of claim 13, wherein the therapeutic moiety is a radioisotope, a toxin, a chemotherapeutic agent, an immune stimulant, or a cytotoxic agent.

### Claim 16 (depends on 13)

The method of claim 13, wherein the individual has ovarian cancer or prostate cancer.

### Claim 17

A method of producing immune-activated cells directed toward a hepsin protein variant, comprising:
exposing dendritic cells to a hepsin protein variant with a sequence shown in SEQ ID NO: 195 or peptide variant therefrom, wherein the exposure activates the immune cells and produces immune-activated cells directed toward the hepsin protein variant.

### Claim 18 (depends on 17)

The method of claim 17, wherein the peptide variant amino acid sequence is shown in SEQ ID NO: 196

### Claim 19 (depends on 17)

The method of claim 17, wherein the dendritic cells are isolated from an individual prior to the exposure, wherein said activated dendritic cells are reintroduced into the individual subsequent to the exposure.

### Claim 20 (depends on 17)

The method of claim 17, wherein the individual has or is at risk of getting ovarian cancer, lung cancer, prostate cancer, or colon cancer.
